Sarcopenia treatment is unusual among chronic conditions in that the best-supported intervention is not a drug, and no drug has been approved for it at all. That is the honest starting position.
Key takeaways
- The 2018 international clinical practice guidelines make one strong recommendation for treating sarcopenia: prescription of resistance-based physical activity.
- Protein supplementation or a protein-rich diet carries a conditional recommendation. Vitamin D supplementation and anabolic hormone prescription received no recommendation either way, on the grounds that the evidence did not support one.
- The PROT-AGE position paper recommends at least 1.0 to 1.2 g of protein per kg of body weight per day for people over 65, more for those exercising, and 1.2 to 1.5 g/kg/day in acute or chronic disease, with severe kidney disease as an explicit exception.
- SPRINTT, a 1,519-participant European trial, found a multicomponent exercise and nutrition intervention reduced mobility disability in frail older adults with the lower baseline function scores.
- No drug is approved anywhere for sarcopenia. Bimagrumab increased lean body mass by 7% against 1% on placebo and produced no significant difference in physical performance.
What the sarcopenia treatment guidelines recommend
The most direct answer available comes from the International Clinical Practice Guidelines for Sarcopenia, published by the ICFSR task force in 2018 and graded using the GRADE system.
The task force reviewed eight topics, including physical activity prescription, protein supplementation, vitamin D supplementation, anabolic hormone prescription and medications under development. Their treatment conclusions were short.
| Intervention | Guideline position |
|---|---|
| Resistance-based physical activity | Strong recommendation for |
| Protein supplementation or a protein-rich diet | Conditional recommendation for |
| Vitamin D supplementation | No recommendation given |
| Anabolic hormone prescription | No recommendation given |
| Other treatment options | Insufficient robust evidence to grade |
That table is the whole picture as far as graded guidance goes, and it explains why so much sarcopenia content online outruns the evidence. Two of the most heavily marketed categories, vitamin D and hormones, were assessed and received no recommendation in either direction.
Resistance exercise, and why it leads
Resistance training is the only intervention in the guideline carrying a strong recommendation, and the reasoning is mechanistic as well as empirical. Muscle is maintained by mechanical loading. Remove the load and it is downregulated within days, which is why the bed rest literature shows double-digit strength losses in healthy older adults over ten days.
A 2025 review of muscle disuse atrophy reaches the same conclusion from the other direction, identifying resistance training as the most effective intervention for reversing lost mass and strength while noting that some patients cannot manage intensive exercise. That caveat is why what is prescribed for a robust 68-year-old and for someone recently discharged after a fracture are not the same programme.
Anyone with sarcopenia or at risk of it needs that prescription written by a clinician or physiotherapist who has assessed them, particularly where falls risk, cardiac disease or recent surgery are involved.
Protein and nutrition
The nutritional side has a conditional recommendation behind it, and a widely cited set of figures.
The PROT-AGE Study Group position paper, published in 2013 by an international group appointed by the European Union Geriatric Medicine Society, recommends that people over 65 take an average daily intake at least in the range of 1.0 to 1.2 g of protein per kg of body weight per day to help maintain and regain lean body mass and function. It advises a higher intake, 1.2 g/kg/day or more, for those who are exercising and otherwise active, and 1.2 to 1.5 g/kg/day for most older adults with acute or chronic disease.
The paper also states an explicit exception. Older people with severe kidney disease, meaning an estimated GFR below 30 mL/min/1.73 m2 who are not on dialysis, may need to limit protein intake. That exception matters, because it is exactly the population most likely to encounter high-protein advice online and least likely to be safe following it. Protein targets are a conversation to have with a clinician who knows your kidney function.
PROT-AGE also recommends both endurance and resistance exercise at individualised levels that are safe and tolerated, which is a reminder that the nutritional recommendation was never intended to stand alone.
What a full programme achieved in trial
The largest test of the combined approach is SPRINTT, published in the BMJ in 2022. It randomised 1,519 community-dwelling adults aged 70 or over with physical frailty and sarcopenia across 16 sites in 11 European countries, comparing a multicomponent intervention of moderate-intensity physical activity plus personalised nutritional counselling against education on healthy ageing.
Among participants with the lower baseline function scores, mobility disability occurred in 21.0% of the intervention group against 25.0% of controls. Physical performance favoured the intervention by 0.8 points on the Short Physical Performance Battery at 24 months and 1.0 point at 36 months. Women in the intervention arm lost less appendicular lean mass than controls at both time points. In participants who started with better baseline function, the intervention did not show a benefit.
That is a real but modest effect, achieved over years, in a population selected for being at risk. It is the most honest picture available of what current treatment can do.
Where drug treatment stands
No medicine is approved for sarcopenia in any major market. The reason is not that nothing was tried.
The clearest single result is bimagrumab, an antibody against the activin type II receptor, tested against optimised standard of care in community-dwelling older adults with sarcopenia and published in JAMA Network Open in 2020. Across 180 participants aged 70 and over at 38 sites in 13 countries, bimagrumab increased lean body mass by 7% against 1% with placebo, and decreased fat mass. On the primary outcome, change in Short Physical Performance Battery score at 24 weeks, there was no significant difference between groups. Both groups improved. The authors concluded that the effects of sarcopenia can be reduced with proper diet and exercise.
An earlier phase II proof-of-concept study had pointed the same way. The pattern across the field has been consistent: the pathway moves mass reliably and function unreliably. Our pages on bimagrumab, apitegromab and myostatin and sarcopenia go through the individual programmes.
Treating what is driving it
EWGSOP2 distinguishes primary sarcopenia, where ageing is the only evident cause, from secondary sarcopenia driven by systemic disease, immobility or inadequate intake. Where a secondary cause is present, addressing it is part of treatment rather than an afterthought.
That includes managing the underlying condition, reviewing medications with the prescriber where a drug may be contributing, restoring adequate energy intake, and mobilising people early after illness or surgery. None of it is exotic, and all of it is better evidenced than most of what is sold for muscle loss.
Where myostatin fits
This site covers the myostatin pathway, so it is worth being precise about what it offers a person with sarcopenia today, which is nothing purchasable.
Myostatin, or GDF-8, restrains muscle growth, and the 1997 Nature paper showing that mice without it grew far larger muscles launched the entire therapeutic effort. Three decades on, the trials have delivered lean mass without matching functional gains, no regulator has approved a myostatin-pathway drug for sarcopenia, and the compounds sold online under related names are unapproved research chemicals with no efficacy data in this condition. Read the trial record rather than the marketing.
Frequently asked questions
What is the most effective treatment for sarcopenia?
Resistance-based physical activity. It is the only intervention that received a strong recommendation in the 2018 international clinical practice guidelines for sarcopenia, and a 2025 review of disuse atrophy separately identifies resistance training as the most effective intervention for reversing lost mass and strength. The programme itself should be prescribed by a clinician or physiotherapist who has assessed the individual.
Is there a drug for sarcopenia?
No approved one. Several candidates targeting the myostatin and activin receptor pathway have been trialled. Bimagrumab increased lean body mass by 7% against 1% on placebo in a randomised trial of older adults with sarcopenia, but showed no significant difference from placebo on the primary physical performance outcome. No medicine currently holds an approval for sarcopenia.
How much protein do the guidelines suggest for older adults?
The PROT-AGE position paper recommends at least 1.0 to 1.2 g per kg of body weight per day for people over 65, 1.2 g/kg/day or more for those who are exercising and active, and 1.2 to 1.5 g/kg/day for most older adults with acute or chronic disease. It explicitly excepts people with severe kidney disease not on dialysis, who may need to limit protein. Anyone with kidney disease should set protein intake with their clinician.
Does vitamin D treat sarcopenia?
The ICFSR task force reviewed vitamin D supplementation as a treatment for sarcopenia and gave no recommendation for or against it, on the basis of the available evidence. That is not the same as saying vitamin D is unimportant in older people generally, where it is prescribed for other reasons. It means it was not supported as a sarcopenia treatment.
Can sarcopenia be reversed?
Trial evidence supports slowing and partially improving it rather than curing it. In SPRINTT, a multicomponent exercise and nutrition programme reduced mobility disability and improved physical performance scores in frail older adults with lower baseline function over two to three years, but did not benefit those who started with better function. Improvement is realistic; reversal is not the framing the evidence supports.
Sources
- Dent E et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging 2018;22(10):1148-1161
- Bauer J et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14(8):542-59
- Bernabei R et al. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ 2022;377:e068788
- Rooks D et al. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial. JAMA Netw Open 2020;3(10):e2020836
- Rooks D et al. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. J Am Geriatr Soc 2017;65(9):1988-1995
- Cruz-Jentoft AJ et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing 2019;48(1):16-31
- Yeo D. Muscle Disuse Atrophy. Adv Exp Med Biol 2025;1478:157-183
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
This article is for educational purposes only and is not medical advice. It reports what published guidelines and clinical trials say, and it does not recommend any exercise programme, protein intake, supplement or medicine for any individual. Exercise prescription and protein targets in older adults, particularly with kidney disease, cardiac disease, recent fracture or recent surgery, must be set by a qualified healthcare professional who has assessed you. Do not start, stop or change any treatment on the basis of this page.